David Sallman, MD, Moffitt Cancer Center, Tampa, FL, outlines the current challenges in bringing CAR-T therapies to myeloid malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Dr Sallman highlights two concerns; the lack of a uniform target antigen, and poor T-cell fitness and function, the former he suggests could be overcome by developing cellular therapies targeting more than one antigen. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.